spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Phillips-Medisize Enters Agreement with Global Pharmaceutical Company to Acquire Exclusive Ownership of Patents for an Innovative Mini-tablet Dispenser

Phillips-Medisize



HUDSON, WI – September 10, 2019 – Phillips-Medisize, a Molex company, announced today an agreement with a Global Pharmaceutical Company, where Phillips-Medisize acquired exclusive ownership of patents supporting an innovative mini-tablet dispenser to accommodate the varied and customized oral dispensing needs of patients.

“Through its unique working principle, the mini-tablet dispenser will be valuable in pediatrics, geriatrics and oncology where patients often require highly flexible oral dosing based on age, weight and other variables,” said Matt Jennings, CEO and President, Phillips-Medisize. “Furthermore, in smaller patient populations the option to flexibly count to combine incremental mini-tablet doses offers an advantage over preparing multiple fixed oral tablet dose strengths.”

The mini-tablet dispenser differentiates itself from most available systems that predominantly rely on volumetric measuring principles. With the assistance of this dispenser mounted on top of a standard tablet bottle, a patient or caregiver will be able to count and dispense mini-tablets in predetermined amounts from one to twenty tablets, and it supports tablets of approximately 2x2 mm to 2.3x2.3 mm dimensions. The mini-tablet dispenser enables the user to visually confirm the measured tablet count number before dispensing and is designed to minimize damage or crushing of the mini-tablets during dispensing.

Phillips-Medisize has begun industrialization preparations aiming to make the dispenser available to an array of pharmaceutical companies globally in early 2020.

About Phillips-Medisize

Phillips-Medisize, a Molex company, is an end-to-end provider of innovation, development and manufacturing solutions to the pharmaceutical, diagnostics, medical device and specialty commercial market segments. Backed by the combined global resources of Molex and its parent company Koch Industries, Phillips-Medisize’s core advantage is the knowledge of its people to integrate design, molding, electronics, and automation, providing innovative, high-quality manufacturing solutions. For more information, please visit www.phillipsmedisize.com

phone +31 252 576 888
email eu_sales@phillipsmedisize.com
web www.phillipsmedisize.com
email Edisonstraat 1 Hillegom 2181 AB
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Merck to Provide BioReliance® End-to-End Solutions to Phanes Therapeutics

• Collaboration to accelerate development and manufacturing of Bispecific Antibody • Merck plans to offer Phanes a full suite of products and services under its BioReliance® offering
More info >>


White Papers

Biosimilars In Emerging Markets: Is It A Level Playing Field?

PRA Health Sciences (PRA)

Governments, healthcare payers, and social and health reforms, combined with the increased incidence of conditions such as cancer and diabetes are paving the way for increased uptake of biologic medicines in emerging markets. However, expensive biologic medicines can be prohibitive to many patients, creating a high level of unmet clinical need. At its best, the global expansion of biosimilars can mean a robust and steady supply of existing and new drugs reaching far-flung patient populations, but localized biosimilar drug developments, especially in China and India, combined with a lack of robust pharmacovigilance systems, threaten to derail the industry by putting patient health at risk.
More info >>

Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement